Growth Equity vs Venture Capital: A 2026 Playbook for LMM Operators

Updated Q3 2026 by CT Acquisitions.

Growth equity vs venture capital is a live decision for any lower-middle-market operator with $3M or more in revenue, positive or near-positive EBITDA, and a real growth plan that needs $10M to $150M of outside capital. Pick the wrong bucket and you will spend six months meeting funds that cannot underwrite your business, then take a term sheet that misprices your risk. This guide is built for the LMM operator, not the pre-seed founder. It walks the definitions, the fit criteria, the 2024-2026 comps, the named sponsors, and the process that CT Acquisitions runs when we place minority growth capital into a client business. Read this before you take the first call from a fund.

In our experience advising LMM operators on growth equity vs venture capital, the single most common mistake is treating the two as points on a continuum. They are different products with different underwriting, different governance, and different exit assumptions. A $12M EBITDA business does not “graduate” from venture capital into growth equity. It was never a venture business. It was always a growth-equity or private-equity candidate that happened to be family-funded. The right question is not which round is bigger. It is which capital source is designed for the risk profile you are actually asking someone to underwrite.

What is growth equity vs venture capital?

Growth equity is minority equity capital, usually $10M to $200M, invested into profitable or near-profitable companies with proven unit economics. Venture capital is equity into pre-profit, pre-scale companies where a substantial fraction of investments are expected to fail and the winners return the fund. Firms like Summit Partners and TA Associates run growth-equity playbooks. Firms like Sequoia and Andreessen Horowitz run venture playbooks. Same asset class, different products.

The industry vocabulary is imprecise, so definitions matter. Growth equity, sometimes called growth capital or expansion capital, refers to minority investments of roughly $10M to $200M into companies that already have real customers, real revenue, and either positive EBITDA or a demonstrated path to it. The underwriting is closer to private equity than to venture capital. According to PitchBook’s 2024 US PE Breakdown, growth equity accounted for roughly 21% of US private-equity deal count in 2024, with median check sizes around $32M.

Venture capital, by contrast, funds companies before the business model is proven. Seed, Series A, and much of Series B are designed to underwrite losses in exchange for optionality on category creation. The NVCA 2024 Yearbook shows US venture invested $170.6 billion in 2023, with roughly 45% of that going to companies that were expected to burn cash for another 24 to 36 months. That is a different product from the one Bain Capital Growth or JMI Equity offer.

For an LMM operator, the practical distinction is this. If the fund’s return model requires that your enterprise value grow 10x in five years, you are being pitched venture capital. If the fund’s return model requires that your enterprise value grow 2.5x to 4x in five years and pay for itself through cash flow if the exit slips, you are being pitched growth equity. Ask that question on the first call.

Who typically uses growth equity vs venture capital?

Growth equity is used by profitable LMM operators, bootstrapped software founders past $10M ARR, and family-owned businesses raising a partial-liquidity recap. Venture capital is used by pre-revenue and early-revenue technology founders whose primary constraint is capital, not customer acquisition. The audience overlap is small. Most LMM businesses in industrials, healthcare services, distribution, or specialty finance are simply not venture candidates, regardless of growth rate.

The typical growth-equity target in 2026 has $20M to $150M of revenue, is growing 20% to 60% annually, generates cash or is within 12 months of cash generation, and is founder-led or founder-plus-partner-led. It has never taken institutional capital. It is not headquartered in Palo Alto or Menlo Park. Its customers are real businesses buying a real product. Look at the recent portfolios of TA Associates or Summit Partners and the pattern is obvious.

The typical venture target has $500K to $10M of ARR, is growing 100%+ annually, is burning cash intentionally to acquire market share, and has already raised at least one prior institutional round. It has a technology moat that requires ongoing R&D investment. It is in a category where a fast-follower can copy the product in 18 months if you slow down, so speed is the strategy.

These are not the same customer. A $12M revenue heating and cooling roll-up in Ohio growing 30% is a growth-equity or private-equity candidate. A $12M ARR vertical SaaS company growing 90% with $8M of net revenue retention is a venture candidate that might also attract growth equity. A $12M revenue specialty chemicals distributor growing 15% is a control-buyout candidate that neither growth equity nor venture capital will look at seriously.

How does growth equity compare to venture capital on structure and terms?

Growth equity uses non-participating preferred stock with a 1x liquidation preference, minority board representation, and standard protective provisions. Venture capital uses similar mechanics on paper but stacks preferences across rounds. By Series D a venture cap table often carries 3x to 5x cumulative liquidation preference over common. Growth equity’s single round of preference sits on top of common with no stacking. That difference matters most at exit, especially in a down or sideways outcome.

The term-sheet mechanics look similar on the first read. Both use preferred stock. Both include liquidation preferences, anti-dilution protection, information rights, and pro rata rights. The difference is cumulative. A company that has closed Series Seed, A, B, C, and D has five layers of preferred stock, each with its own preference and its own protective provisions. Founders who read NVCA’s model documents often do not appreciate how quickly the stack compounds against common shareholders.

Growth equity typically involves a single round. One class of preferred sits above common. One board seat. One set of protective provisions. If a follow-on is needed, it is usually done as a rollover or an extension of the same round at a similar valuation, not a new priced round with a new stack. See our detailed breakdown at what is a term sheet for the mechanics.

Consider a $75M enterprise value company selling for $100M in five years. If the company took $25M of growth equity at a $75M pre-money valuation with 1x non-participating preference, the growth-equity fund gets its $25M back and 25% of the remaining $75M, so $43.75M. The founder and common get $56.25M. If the same company had taken $25M of venture capital across multiple rounds with cumulative 2x participation stacked to $50M of aggregate preference, the venture stack takes $50M plus a participating share of the remainder. The common stack takes a fraction of what growth-equity common would take. This is the outcome that surprises operators who do not model the down-case.

When does growth equity vs venture capital make sense for an LMM operator?

Growth equity makes sense when you are profitable, growing 20%+ annually, and would rather retain control and take partial liquidity than sell outright. Venture capital makes sense when you have a category-creating technology, you need $50M+ of runway to build a moat, and you accept that founder dilution will exceed 60% by exit. Very few LMM businesses genuinely fit the second profile, even in software.

Five clear fit criteria for growth equity, in order of importance. First, positive or near-positive EBITDA on a run-rate basis. Second, revenue growth of at least 15% annually organically or 25% with acquisition. Third, a founder or management team that wants to stay for another 3 to 7 years. Fourth, a use of proceeds that is not primarily to fund operating losses. Fifth, a plausible exit path in 4 to 6 years to a strategic buyer, private-equity buyer, or public market.

Five clear fit criteria for venture capital. First, a technology or product moat that is legitimately hard to replicate. Second, a market that is being created rather than being served. Third, willingness to burn cash for 24 to 60 months. Fourth, willingness to accept 50%+ founder dilution over the arc of the company. Fifth, willingness to be replaced as CEO if the board thinks scaling requires it.

An LMM operator running a $30M revenue specialty coatings business that is growing 25% and generating $6M of EBITDA is a growth-equity candidate. A pre-revenue synthetic biology team out of MIT is a venture candidate. A profitable $8M ARR vertical SaaS company growing 60% is a both-are-plausible candidate, and the choice comes down to whether the founder wants to keep control and take liquidity or bet on a much larger outcome with a much larger stack of preferred above them.

How much does growth equity vs venture capital cost in dilution and dollars?

A growth-equity round dilutes founders 15% to 40% in a single close. A comparable venture path from Series A through D typically compounds to 50% to 70% dilution before an option pool refresh. Cash cost of the round runs 5% to 7% of gross proceeds for growth equity, versus 3% to 5% per round for venture, but venture involves four to six rounds, so cumulative venture cost frequently exceeds growth-equity cost by 200 to 400 basis points.

Model both paths side by side. A company raising $30M in one growth-equity round at a $70M pre-money valuation is 30% diluted. A company raising $30M in venture across three rounds at $15M pre, $40M pre, and $100M pre, with $5M, $10M, and $15M rounds respectively, plus an option pool refresh at each round, ends up 55% to 65% diluted after all rounds close. The venture path may raise more total dollars over time, but at the cost of significantly higher founder dilution and a much larger preferred stack.

Cost component	Growth equity ($30M round)	Venture (Series A+B+C, $30M cumulative)
Founder dilution	25% to 35%	50% to 65% cumulative
Board seats to investors	1 to 2	3 to 5 across rounds
Advisor fees	3% to 5% of proceeds	0% to 2% per round
Legal fees	$250K to $600K single close	$150K to $400K per round
Quality of earnings	$75K to $200K	Rarely required at Series A/B
Liquidation preference	1x non-participating single round	1x per round, cumulative
Time to close	16 to 26 weeks	10 to 16 weeks per round
Cumulative fee load	5% to 7% of gross proceeds	8% to 12% across all rounds

The dilution math is deterministic. According to Carta’s State of Private Markets Q4 2024, the median dilution per venture round in 2024 was 19.5% at Series A, 15.8% at Series B, and 12.9% at Series C. Compound those with an option pool refresh at each round and the cumulative founder dilution is a straightforward calculation.

Who provides growth equity vs venture capital to LMM businesses?

Growth-equity providers to LMM businesses include Summit Partners, TA Associates, JMI Equity, Susquehanna Growth Equity, Spectrum Equity, Frontier Growth, and Serent Capital. Family offices like Pritzker Private Capital and BDT & MSD Partners provide similar minority checks. Venture funds active in later-stage growth include Insight Partners, General Atlantic, and Battery Ventures. Each firm has a specific check size, sector focus, and control preference. The named list below reflects 2024-2026 activity.

Firm	Type	Focus	Typical check
Summit Partners	Growth equity	Software, healthcare, financial services	$25M to $250M
TA Associates	Growth equity	Software, financial services, healthcare, consumer	$50M to $500M
JMI Equity	Growth equity	B2B software	$20M to $150M
Susquehanna Growth Equity	Growth equity	Software and information services	$10M to $75M
Spectrum Equity	Growth equity	Internet-enabled software and services	$25M to $150M
Frontier Growth	Growth equity	B2B software $5M to $30M ARR	$15M to $75M
Serent Capital	Growth equity	Tech-enabled services and software	$15M to $150M
Insight Partners	Late-stage VC and growth	Software across stages	$25M to $500M+
General Atlantic	Growth equity	Global, cross-sector	$50M to $500M+
Battery Ventures	Venture and growth	Software, industrial tech, consumer	$20M to $200M
Pritzker Private Capital	Family office	Family-owned businesses, manufacturing, services	$100M to $500M
BDT & MSD Partners	Family office / merchant bank	Family and founder-led businesses	$100M+

The list is not exhaustive. Firms like Providence Strategic Growth, Silversmith Capital, Mainsail Partners, and PSG Equity are active in the software growth-equity space. In healthcare services, Water Street Healthcare Partners and Nautic Partners run adjacent minority-and-control books. In industrials and business services, Peak Rock Capital, KKR Growth, and Blackstone Growth participate at check sizes above $50M. See family office vs PE buyer for a deeper comparison of governance and hold periods.

How does the growth-equity vs venture-capital process actually work?

The growth-equity process runs 16 to 26 weeks and follows a structured competitive auction. Venture rounds run 8 to 16 weeks and follow a warm-intro-driven pattern where founders meet 20 to 40 funds sequentially. The growth-equity process resembles a sell-side M&A process at smaller scale, with a confidential information memorandum, management presentations, indications of interest, and a term-sheet negotiation. Venture rounds skip most of that structure.

The typical CT Acquisitions growth-equity process looks like this. Week 1 to 3, engagement, financial cleanup, and preparation of a confidential information memorandum plus a data room. Week 4 to 6, targeted outreach to 40 to 80 pre-qualified funds and family offices. Week 7 to 10, management presentations with the 12 to 20 funds that engage. Week 11 to 14, indications of interest and selection of two to four finalists. Week 15 to 20, on-site diligence, quality of earnings, and technical or commercial diligence. Week 21 to 26, term sheet, legal drafting, and close.

1. Advisor engagement and scope of raise. Define primary vs secondary split, minimum acceptable price, and control preferences.
2. Financial cleanup. GAAP conversion if needed, working-capital normalization, one-time-item mapping.
3. Confidential information memorandum. 40 to 60 page CIM plus a 3 to 5 year projection model.
4. Data room build. Historical financials, contracts, employee census, customer concentration, IP schedule, litigation, tax.
5. Fund and family office targeting. Screen 200 to 400 candidates down to 40 to 80 that fit your check size, sector, and geography.
6. Teaser and CIM release under NDA to the target list.
7. Management meetings with 12 to 20 engaged funds, usually a 90-minute video plus follow-up questions.
8. Indications of interest, typically 6 to 10 IOIs across a 20% valuation range.
9. Down-selection to two to four finalists for in-person or extended-diligence sessions.
10. On-site diligence and management dinners with finalists.
11. Quality of earnings, commercial diligence, and legal diligence in parallel.
12. Term sheet negotiation with the leading finalist, with a live backup process.
13. Definitive documentation, including purchase agreement, shareholders’ agreement, and employment terms.
14. Signing and close, with wire, share issuance, and board seating.

See raise capital and M&A advisory for related process work. For a compare with sell-side, see lower-middle-market M&A advisor.

What paperwork does a growth-equity vs venture-capital raise require?

A growth-equity close typically requires a stock purchase agreement, an amended and restated shareholders’ agreement, a new charter, updated employment agreements for key executives, and closing certificates. Venture rounds use similar documents but standardized through the NVCA model set. Growth-equity documents are usually bespoke, negotiated line by line, and average 250 to 400 pages of definitive documentation.

The document stack for a growth-equity round typically includes the following. Stock purchase agreement, running 60 to 120 pages. Amended and restated certificate of incorporation, 15 to 30 pages. Amended and restated stockholders’ agreement, 40 to 80 pages. Investor rights agreement, 20 to 40 pages. Voting agreement, 10 to 20 pages. Right of first refusal and co-sale agreement, 15 to 25 pages. Employment agreements for the CEO and other key executives, 15 to 30 pages each. Restrictive covenant agreements. Closing certificates and opinions.

Venture rounds use the NVCA model documents as the starting point. The result is more standardized and slightly faster to negotiate, but the underlying complexity is similar once you get past Series B. Founders often underestimate the effort involved in negotiating protective provisions and drag-along thresholds in venture rounds because the NVCA templates lull them into thinking the terms are pre-agreed.

Legal cost tracks document count and negotiation intensity. Budget $250K to $600K for a growth-equity round with a name-brand law firm on both sides. Budget $150K to $400K for a Series B or C venture round. Fees for a smaller Series A can be $75K to $200K if both sides use standard NVCA documents without heavy custom drafting.

What are the tax and legal implications of growth equity vs venture capital?

A minority equity investment is generally not a taxable event for the company or existing shareholders on the primary portion. Secondary purchase, where founders sell existing shares, is a taxable capital-gains event to the seller. QSBS qualification under IRC Section 1202 can exempt up to $15M of gain per shareholder if the company is a qualified C-corp held for 5+ years, per the OBBBA update effective 2025.

The primary tax lever LMM founders should understand is IRC Section 1202 Qualified Small Business Stock. If your company is a domestic C-corporation with gross assets under $75M at the time of stock issuance and you hold the shares for at least five years, up to $15M of gain per shareholder is federally tax-free under the July 2025 One Big Beautiful Bill Act update. That is a material planning consideration for founders taking secondary. The 5-year clock does not reset on secondary shares held for the required period.

On the corporate side, an equity investment does not generate cancellation of debt income or ordinary income to the company. It does, however, trigger updated stockholder tracking, Section 382 ownership-change testing if a large enough position is issued, and, in a C-corp, potentially the constructive ownership rules under Section 318. Consult your tax advisor before you finalize a cap table because Section 382 can lock up your net operating losses if the ownership change exceeds 50% over a three-year testing period.

Legal implications include increased corporate governance obligations, protective provisions on decisions like debt incurrence and executive compensation, and information rights that require monthly or quarterly reporting. Any founder who has never issued audited financials will feel the reporting burden immediately. Plan for a controller or CFO upgrade if you do not already have one.

What are the common structures and terms in growth equity vs venture capital?

Growth-equity structures usually involve non-participating preferred stock with 1x liquidation preference, one to two board seats, standard protective provisions, and drag-along rights triggered at 50% or more of preferred plus common. Venture-capital structures use similar mechanics but stack across rounds. Anti-dilution is broad-based weighted average in almost all growth-equity rounds and roughly 80% of venture rounds per the 2024 Fenwick Silicon Valley Venture Survey.

Term-sheet mechanics worth understanding line by line. Liquidation preference determines who gets paid first at exit. Non-participating means preferred takes either its preference or its as-converted share of proceeds, whichever is larger. Participating means preferred takes its preference plus its share of the remainder. Growth equity is almost always non-participating. Venture is mixed, with participating preferences more common in bridge rounds and down rounds.

Anti-dilution protection kicks in if you raise a future round at a lower price. Broad-based weighted average is the standard and is founder-friendly relative to full ratchet, which is punitive. See Fenwick’s Q4 2024 Silicon Valley Venture Capital Survey for current market frequency, which shows broad-based weighted average in 96% of tracked deals.

Protective provisions are the list of decisions the investor can veto. Standard items include debt incurrence above a threshold, executive comp changes, issuance of new stock, changes to the charter, sale of the company, and material acquisitions or dispositions. Overly broad protective provisions can effectively give a minority investor a control veto on ordinary-course operating decisions. Read them line by line.

Drag-along rights force minority shareholders to sell in a company sale if a majority approves. Standard drag triggers require both a majority of the preferred and a majority of the common. Some funds try to draft drag triggers that require only a majority of the preferred, which is an effective control provision inside a minority-equity wrapper. Reject that if you see it.

What are the red flags to avoid in growth equity vs venture capital term sheets?

Watch for participating liquidation preference above 1x, full-ratchet anti-dilution, drag-along triggers that require only preferred approval, protective provisions on ordinary-course operating decisions, forced pay-to-play penalties, and any term that shifts economic risk from the fund to founders. In 2024-2026 growth equity, these terms are uncommon in top-of-market rounds but appear in single-sourced deals or in structured processes where the founder has no leverage.

Six specific red flags to flag on any term sheet review. First, participating preferred at 2x or higher, which double-dips at exit. Second, full-ratchet anti-dilution, which resets the investor’s price to any future round price regardless of size. Third, drag rights that trigger on preferred-only vote, which is functional control. Fourth, protective provisions that cover items like hiring vice presidents or opening new offices. Fifth, milestone-based tranches where the fund can walk if you miss a quarter. Sixth, expense reimbursement caps set below likely diligence spend, which shifts diligence cost onto the founder.

Additional watchpoints include most-favored-nation provisions that let the investor upgrade to any better terms offered to a later investor, cumulative dividends that accrue whether declared or not, and mandatory redemption rights that force a buyback at year 5 to 7. Cumulative dividends in particular can add 20% to 40% to the fund’s effective preference over a five-year hold. See mezzanine debt for acquisitions guide for how similar mechanics work in debt structures and why they cost founders more than they appear at first read.

What are the 2024-2026 market dynamics for growth equity vs venture capital?

The 2024-2026 period pushed growth equity into a structural bull cycle and pressured venture capital. Higher rates cut into venture returns and lengthened hold periods, while growth equity benefited from operators who needed capital but did not want to sell control at trough multiples. Growth-equity dry powder crossed $500B globally in 2024 per PitchBook. Venture dry powder deployed at the slowest pace since 2019.

The macro picture matters because it changes what founders can extract at term sheet. According to PitchBook’s 2024 US PE Breakdown, US growth-equity deal count fell 8% in 2024 but median check size increased 22% as funds concentrated capital in higher-conviction deals. This means fewer deals get done, but the deals that get done are larger and better priced for the seller.

Named 2024-2026 growth-equity deals worth studying. Summit Partners led a $250M investment into Alignment Healthcare in June 2024 at a $1.8B pre-money valuation, mixed primary and secondary, per Summit Partners’ announcement. TA Associates led a $500M investment into Rimes Technologies in Q3 2024, all primary, per TA Associates news. General Atlantic invested $250M into Sagility Health in October 2024 alongside its IPO, per General Atlantic press release. Insight Partners led a $200M growth round into Fivetran in Q1 2025 per Insight Partners newsroom. These are the reference points to use when a fund tries to anchor your valuation.

On the venture side, NVCA data for 2024 showed total US venture deal count fell 21% year over year, with median Series B valuations dropping 18%. Late-stage venture became increasingly bimodal, with AI-adjacent companies attracting premium multiples and non-AI companies facing compressed valuations. Bain’s 2025 Global Private Equity Report confirmed the diverging trend and projected another 12 to 18 months of the same pattern.

Practical implication for LMM operators. If your business is not AI-adjacent, growth equity is likely to price your business more attractively than venture capital would in the current market. If your business is AI-adjacent and pre-profit, you may find genuinely competitive term sheets from both camps and can play them against each other. See growth equity vs private equity for the parallel decision if your business is more mature.

How does CT Acquisitions help you find the right equity partner?

CT Acquisitions runs a targeted, competitive process against 40 to 80 growth-equity funds, family offices, and structured-capital investors per raise. We handle CIM preparation, financial cleanup, targeted outreach, management-meeting choreography, IOI negotiation, diligence coordination, and term-sheet negotiation. Typical LMM raise closes in 16 to 26 weeks. Our success fee ranges from 3% to 5% of proceeds, tiered against a Lehman formula.

The value of an experienced capital advisor is measured in three ways. First, price. A competitive process against 8 to 12 engaged funds typically lifts the winning bid 15% to 30% versus a single-sourced deal. Second, terms. Advisors who have negotiated 50+ term sheets know which provisions to fight, which to concede, and which to leave alone. Third, time. A structured process closes in 16 to 26 weeks with a defined path. An unstructured process often runs 40+ weeks and ends without a close.

CT Acquisitions’ approach is process-driven. We do not shop a business to every fund in our database. We pre-qualify a target list of 40 to 80 funds based on your check size, sector, geography, control preference, and existing portfolio conflicts. We then run a compressed outreach window of 4 to 6 weeks to force funds to prioritize the opportunity. This is how selling to a growth-equity investor works in practice.

Beyond growth equity we can also structure hybrid capital raises. See unitranche debt acquisition financing, business acquisition loan, and leveraged buyout acquisition financing guide for related capital-stack alternatives that we regularly model against pure equity options.

How do you choose among competing capital advisors?

Evaluate capital advisors on five dimensions. First, track record of closed deals in your sector and check size. Second, breadth and quality of investor relationships. Third, quality of the CIM and financial-model work product. Four, alignment on success fees and expense reimbursement. Fifth, personal fit with the deal partner who will actually run your process. Ignore firm brand in isolation. A boutique with a deep vertical is usually more effective than a bulge bracket that treats a $50M raise as a training assignment.

Nine evaluation questions to ask before signing an engagement letter. What is your deal-count in my check size and sector over the last 24 months. Which specific partner will run my process day to day. How many other active mandates does that partner have right now. What is your process for CIM drafting and how many revisions before it is investor-ready. What is your targeted fund and family office list and can I see it before we launch. What is your success fee structure and does it include a Lehman formula. How is expense reimbursement handled. What is your policy on parallel tracks like debt or sell-side. What happens if we abandon the process midway.

Reference-check the advisor with two closed clients and one client where the process was abandoned. Talking to a lost deal is more informative than a highlight-reel reference. Ask what surprised them, what they wished the advisor had done differently, and whether they would hire the same advisor again. See lower-middle-market M&A advisor and buy-side M&A advisory for related evaluation criteria across other transaction types.

What is the 2024-2026 deal comp set for growth equity vs venture capital?

Recent representative LMM growth-equity deals include the $250M Summit into Alignment Healthcare, $500M TA into Rimes, $250M General Atlantic into Sagility, $200M Insight into Fivetran extension, and $150M JMI into Cvent. Median 2024 growth-equity check per PitchBook was $32M, up 22% from 2023. Median late-stage venture check was $18M, down 14%. The comp set skews larger than most operators expect.

Deal	Investor	Amount	Date	Structure
Alignment Healthcare growth round	Summit Partners	$250M	June 2024	Primary + secondary, minority
Rimes Technologies growth investment	TA Associates	$500M	Q3 2024	Primary, minority
Sagility Health growth investment	General Atlantic	$250M	October 2024	Primary alongside IPO
Fivetran growth extension	Insight Partners	$200M	Q1 2025	Late-stage growth
Diligent Corporation recap	Insight Partners	$400M	Q2 2025	Recap plus growth capital
Applied Systems growth investment	Hellman & Friedman + JMI	$300M	Q4 2024	Minority growth
Instructure investment	KKR Growth	$150M	Q3 2024	Late-stage growth
Cvent follow-on	JMI Equity	$150M	Q4 2024	Minority growth

These deals collectively suggest a 2024-2026 growth-equity market that is active for scaled software and healthcare services businesses at $50M+ revenue. Below $50M revenue the market is thinner and the LMM operator should expect fewer bidders and tighter terms. Above $150M revenue the market is more competitive and the operator should expect broader interest and better pricing. See growth equity vs private equity for the parallel comp set at control-buyout scale.

What does a growth-equity vs venture-capital cap table look like at exit?

A company that took one $30M growth-equity round on a $70M pre-money exits with roughly 70% founder and common ownership plus a 30% growth-equity stake, subject to option pool. A company that took Series A through D venture capital to raise the same cumulative $30M typically exits with 30% to 45% founder ownership, 40% to 55% preferred stack, and a 15% to 25% option pool. The cap table geometry dominates net proceeds at exit.

Model exit proceeds at $200M, $400M, and $800M to see the sensitivity. In a growth-equity structure with $25M invested at 1x non-participating on a $75M pre-money, the fund gets max of $25M or 25% of proceeds. At $200M exit that is $50M to fund and $150M to common. At $400M exit that is $100M to fund and $300M to common. At $800M exit that is $200M to fund and $600M to common.

In a venture structure with $30M invested across four rounds with 1x non-participating preference layered at each round, the aggregate preference stack is $30M and the aggregate preferred ownership is roughly 45% after all rounds and pool refreshes. At $200M exit that is roughly $90M to funds and $110M to common, with common further split with the option pool. At $400M exit that is $180M to funds and $220M to common. At $800M exit that is $360M to funds and $440M to common. Founders in the venture scenario capture materially less at every exit level.

The exception is when venture capital funds a business to a much larger absolute outcome than growth equity could have. A company that raised $100M of venture and exits at $2B may leave founders with more absolute dollars than the growth-equity path would have, even at higher dilution. The question is whether your business can plausibly get to $2B without $100M of capital. For most LMM businesses the answer is no, and growth equity is the higher-expected-value path.

What if your business does not fit growth equity or venture capital?

If your business does not fit growth equity or venture capital, look at private-equity control buyouts, minority family-office recaps, mezzanine debt, unitranche debt, or a full sell-side process. Businesses with strong cash flow but slower growth are typically better served by debt or a control buyout. Businesses with fast growth but no path to profitability are typically better served by strategic capital or continued self-funding.

Decision tree in plain terms. If you have $5M+ EBITDA and are growing 5% to 15%, look at private-equity control buyouts, family-office minority recaps, and mezzanine debt. If you have $5M+ EBITDA and are growing 15% to 40%, growth equity is often the best fit. If you have $5M+ EBITDA and are growing 40%+, both growth equity and late-stage venture are options. If you have negative EBITDA and are growing 40%+, venture is the primary option unless you have a plausible 24-month path to positive EBITDA.

Common alternatives worth modeling. A senior credit facility can fund working capital and modest growth without dilution but requires steady cash flow to service debt. Mezzanine debt sits between senior and equity, priced 11% to 14% cash coupon in 2024-2026 per GF Data reports, and dilutes 5% to 10% via warrants. Unitranche combines senior and subordinated into a single facility and is popular for LMM acquisitions. A full sale to a strategic or PE buyer removes the reinvestment question entirely and lets the founder retire or start over.

CT Acquisitions models all of these paths side by side before recommending a capital strategy. See debt vs equity financing, what are best acquisition financing options, and capital raise for the full menu of structures we build against LMM balance sheets.

How do valuation multiples compare for growth equity vs venture capital?

Growth-equity valuations for software businesses averaged 8.5x to 12x forward revenue in 2024-2026 for high-growth targets and 4x to 7x for slower-growth targets, per PitchBook and Software Equity Group. Venture Series B valuations averaged 15x to 25x forward ARR in the same period, and Series C averaged 12x to 18x. For non-software businesses, growth equity prices on EBITDA multiples of 8x to 15x, while venture capital is largely absent from the market.

Valuation basis	Growth equity 2024-2026	Venture capital 2024-2026
Software forward revenue multiple	4x to 12x	10x to 25x
Software trailing revenue multiple	6x to 18x	15x to 40x
Software EBITDA multiple (if positive)	20x to 40x	N/A pre-profit
Healthcare services EBITDA multiple	10x to 18x	N/A
Business services EBITDA multiple	8x to 14x	N/A
Industrial EBITDA multiple	6x to 12x	N/A
Consumer / retail EBITDA multiple	7x to 13x	Limited

Sources for this compression include Software Equity Group’s 2024 SaaS M&A quarterly reports, PwC’s US M&A outlook 2025, and McKinsey’s Private Equity and Principal Investors insights. The takeaway for an LMM operator is that growth-equity multiples anchor to profitability and steady growth, while venture multiples anchor to ARR growth and pattern recognition on category leadership. The two frameworks yield very different numbers even for the same company on the same day.

What are the common exit paths for growth-equity vs venture-backed companies?

Growth-equity backed companies typically exit through sale to a strategic buyer, sale to a larger private-equity buyer, or IPO. Median hold period is 4 to 6 years per PitchBook. Venture-backed companies exit through IPO, acquisition by a strategic, or shutdown. Median hold period is 7 to 10 years. Growth-equity exit multiples are typically 2.5x to 4x cost. Venture-fund top-quartile exits target 5x to 10x on winners, with losses concentrated in the tail.

Growth-equity funds are structured to return capital in a 4 to 6 year window because their LPs demand it. This forces active portfolio management, board pressure on sale timing, and preference for exits at reasonable multiples over holding for a bigger absolute outcome. Founders considering growth equity should model exit at year 5 as the base case, not year 8 or 10.

Venture funds are structured for 10-year fund lives with 2 to 5 year extensions. This gives them the patience to hold winners longer, which is why venture returns are top-heavy on a small number of category-defining outcomes. The trade-off is that funds pressure exits on non-winners to recycle capital, sometimes at prices below what the founder would prefer to accept.

The IPO path became substantially more selective in 2024-2026. Per EY’s Global IPO Trends, US IPO count remained subdued through 2024 and recovered modestly in 2025 for companies with $200M+ revenue and clear paths to profitability. IPO is now realistically available only to growth-equity backed companies at scale and to venture-backed winners at extraordinary scale. Most exits happen through sale.

What role does structured capital play alongside growth equity vs venture capital?

Structured capital, which sits between straight equity and straight debt, has grown from a niche product to a $100B+ market in 2024-2026 per Preqin. Products include convertible preferred with cash coupons, redeemable preferred, structured equity from firms like HPS Investment Partners and Blackstone Credit, and revenue-based financing at the smaller end. Structured capital is often the right answer for a business that is too profitable for venture and too growth-oriented for pure debt.

Structured equity products worth knowing. Convertible preferred stock with a cash coupon and an equity conversion at exit. Redeemable preferred with a mandatory redemption at year 5 to 7 unless the company sells or IPOs. Structured equity with an equity kicker, often taking the form of penny warrants or performance-vesting shares. Revenue-share arrangements where the investor takes a fixed percentage of revenue until a return threshold is hit.

Providers active in the LMM structured-capital space include HPS Investment Partners, Ares Management, Blackstone Credit, Oaktree Capital, Golub Capital, and Antares Capital at the larger end. At the smaller end, firms like Runway Growth Capital, Silicon Valley Bank’s successor bank, and specialty lenders like Trinity Capital and Hercules Capital provide venture-debt and structured-equity products. Family offices sometimes structure similar deals bespoke.

The economics fall between equity and debt. Cash coupons in 2024-2026 ran 8% to 12% per GF Data. Equity kickers add 5% to 15% of company ownership. Total effective cost of capital typically runs 14% to 22% IRR to the investor, which sits above senior debt but below pure growth equity. For a profitable LMM business that does not want to give up 30% of common ownership, structured capital can be materially cheaper than growth equity on a five-year net-of-cost basis. See mezzanine debt for acquisitions guide and unitranche debt acquisition financing for the debt-adjacent versions.

How should LMM founders think about post-close role and control?

Growth-equity founders typically retain the CEO seat, chair the board, and continue running the company day to day. Venture-backed founders retain CEO through Series B in most cases but are increasingly replaced or supplemented with a professional CEO by Series C or D. Founders considering growth equity vs venture capital should read the post-close operating model as carefully as the price. Control preferences dominate the decision for most LMM operators.

Growth-equity fund governance is deliberately light-touch. One board seat, protective provisions on major decisions, quarterly financial reporting, and an annual budget approval. The fund partner acts as a coach and network resource. Weekly or biweekly check-ins are common but not mandated. The fund does not run your operating meetings or approve your VP hires.

Venture-fund governance escalates through rounds. Series A brings one investor board seat. Series B typically brings a second. Series C often adds a third or an independent seat controlled by the preferred. By Series D, the board is majority-preferred in most cases. Founders considering the venture path should model out how governance changes over five years, not just at Series A.

The practical implication for LMM operators. If you want to run your business for the next five years without an outside board holding operating veto, take growth equity, not venture capital. If you want to hand off operations to a professional CEO within three years and focus on category creation, venture capital is designed for that path. Either is legitimate, but they require different founder profiles.

What does a realistic 5-year hold look like under each path?

A 5-year growth-equity hold typically involves 2.5x to 4x revenue growth, 2x to 3x EBITDA growth, one to three add-on acquisitions, and a competitive exit process at year 4 to 6. A 5-year venture path typically involves 4x to 10x ARR growth, two additional priced rounds of dilution, an option pool refresh, and either an IPO track or a strategic acquisition process. The two operating models produce very different companies at the end of the hold.

Model the growth-equity path with a $30M revenue starting point. Year 1 the company grows 30% to $39M with the same 20% EBITDA margin, generating $7.8M EBITDA. Year 3 the company grows through organic plus one add-on to $65M revenue and $14M EBITDA. Year 5 the company exits at $100M revenue and $22M EBITDA at 12x EBITDA, so $264M enterprise value. Founder common at 65% takes roughly $171M, less debt.

Model the venture path with a $10M ARR starting point growing 60% annually and burning cash to accelerate growth. Year 3 the company hits $40M ARR with $8M of cash burn. Year 5 the company hits $100M ARR profitable at exit. The company sells for 8x forward ARR at $800M or IPOs at similar. Founder common at 30% after all rounds takes roughly $240M, less preference stack, so roughly $200M net.

The venture path produces a bigger absolute number if it works. The growth-equity path produces a more reliable number that survives lower exit multiples. Both are legitimate strategies. The right choice depends on your risk tolerance, your operating preferences, and your realistic assessment of whether your business can execute the venture case. Most LMM businesses cannot, and pretending otherwise leaves money on the table.

Frequently asked questions

Is growth equity better than venture capital for a profitable business?

For a profitable lower-middle-market business with $3M or more in revenue and any positive EBITDA, growth equity is almost always the better fit. Venture capital assumes losses funded by future rounds, board-driven scaling, and preferred stock with participation. Growth equity accepts real cash-flow underwriting, allows partial founder liquidity, and prices at revenue or EBITDA multiples instead of forward ARR.

What EBITDA do you need for growth equity in 2026?

Most growth-equity funds want at least $2M to $5M of run-rate EBITDA, or a clear line of sight to that number within 12 months. Firms like Summit Partners, TA Associates, and Susquehanna Growth Equity will consider bootstrapped software companies without EBITDA if net revenue retention exceeds 110% and Rule of 40 exceeds 40%.

How much of my company will I give up in a growth-equity round?

Growth equity is defined by minority ownership, so dilution typically lands between 15% and 40%. A $25M investment into a $75M pre-money company is 25% dilution. A $50M investment into a $100M pre-money company is 33%. Any deal above 50% ownership is a control buyout, priced and negotiated as private equity, not growth equity.

Can I get partial cash out in a growth-equity deal?

Yes. Secondary purchase, where the fund buys existing shares from founders alongside a primary capital injection, is one of the defining features of growth equity. A common split in 2024-2026 deals is 60% to 70% primary for the balance sheet and 30% to 40% secondary to founders. Venture capital rounds rarely allow this before Series C or D.

Do growth-equity investors take board control?

No. A typical growth-equity term sheet gives the fund one board seat, sometimes two, and a set of protective provisions on major decisions. The founder or CEO retains chair and operational control. This is the practical reason many LMM operators pick growth equity over a private-equity buyout, where the sponsor appoints the majority of the board.

How long does a growth-equity raise take in 2026?

From engagement of a capital advisor to wire, expect 16 to 26 weeks. That includes 3 to 4 weeks of positioning and CIM prep, 4 to 6 weeks of outreach and management meetings, 6 to 10 weeks of diligence and quality of earnings, and 3 to 5 weeks of legal documentation. Rushed processes under 12 weeks usually indicate a single-sourced deal at a discounted valuation.

Should I use an investment banker or raise growth equity directly?

For rounds above $10M, a competitive process run by an experienced sell-side advisor typically increases the winning bid by 15% to 30% and improves non-price terms materially. Below $10M the calculus is closer, but even then a placement agent or M&A advisor is often net positive because they filter tire kickers and negotiate the term sheet. Founders who negotiate solo against a repeat-player fund concede on liquidation preference, tag-along rights, and drag thresholds.

What does growth equity cost in fees and expenses?

Plan for advisor success fees of 3% to 5% of capital raised, legal fees of $250K to $600K, quality-of-earnings work of $75K to $200K, and reimbursed investor diligence expenses of $50K to $150K. Total transaction cost usually runs 5% to 7% of gross proceeds. That is significantly less than a full sell-side M&A process, where all-in cost frequently touches 8% to 10%.

Related reading

• Raise capital
• M&A advisory
• Buy-side M&A advisory
• Lower-middle-market M&A advisor
• Growth equity vs private equity
• Mezzanine debt for acquisitions guide
• Unitranche debt acquisition financing
• Selling to a growth-equity investor
• Family office vs PE buyer
• What is a term sheet
• Business acquisition loan
• Leveraged buyout acquisition financing guide
• Debt vs equity financing
• Capital raise